financetom
Business
financetom
/
Business
/
Cemex's Q1 Results Show Strong EMEA Growth, Offset by Mexican Market Struggles
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cemex's Q1 Results Show Strong EMEA Growth, Offset by Mexican Market Struggles
May 25, 2025 8:04 PM

Cemex shares are trading higher premarket on Monday. The company reported first-quarter net sales of $3.65 million, missing the consensus of $3.80 billion.

Net sales fell 7% year over year (Y/Y), mainly due to lower volumes in Mexico.

Mexico sales declined 25% Y/Y to $981 million, United States sales fell 4% Y/Y to $1.19 billion, Europe, Middle East, and Africa rose 2% Y/Y to $1.07 billion, and South, Central America, and the Caribbean increased 2% Y/Y to $314 million.

EBITDA declined 18% Y/Y to $601 million in the quarter, with a margin contracted 2.0ppt Y/Y to 16.5% in the quarter.

Lower volumes and weather-related maintenance activity impacted the EBITDA margin.

Segment-wise, operating EBITDA fell 27% Y/Y in Mexico, 20% Y/Y in the United States and 3% Y/Y in South and Central America and the Caribbean, while it increased 40% Y/Y in Europe, the Middle East and Africa segment.

Outlook: Cemex expects recurrent yearly EBITDA savings of at least $150 million in 2025 and $350 million by 2027.

Given the macroeconomic uncertainties and anticipated savings from Project Cutting Edge, the company continues to forecast flat EBITDA performance for 2025.

Cemex remained optimistic about volume growth in EMEA and SCAC, anticipates improved performance in Mexico, and expects stable market conditions in the U.S. during the second half of 2025.

The company projects FCF to deliver $500 million in savings in 2025.

Price Action: CX shares are up 2.53% at $6.070 premarket at the last check Monday.

Read Next:

UnitedHealth, T-Mobile And Fiserv Are Among Top 12 Large-Cap Losers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio?

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
FDA Declines To Approve Expanded Use of Dynavax's Hepatitis B Vaccine In Hemodialysis Patients
FDA Declines To Approve Expanded Use of Dynavax's Hepatitis B Vaccine In Hemodialysis Patients
May 14, 2024
Tuesday, Dynavax Technologies Corporation ( DVAX )  provided a regulatory update for its supplemental Biologics License Application (sBLA) to include a four-dose HEPLISAV-B vaccine regimen for adults on hemodialysis.  The FDA has issued a Complete Response Letter stating that the application did not provide sufficient data to fully evaluate the effectiveness or safety of a four-dose regimen of HEPLISAV-B.  The CRL has...
Update: Amazon Says AWS CEO Adam Selipsky to Step Down, Matt Garman to Take Over
Update: Amazon Says AWS CEO Adam Selipsky to Step Down, Matt Garman to Take Over
May 14, 2024
10:07 AM EDT, 05/14/2024 (MT Newswires) -- (Updates to add details in the second and third paragraphs.) Amazon.com ( AMZN ) announced Tuesday that Adam Selipsky will step down as chief executive of AWS and that Matt Garman will replace him, effective June 3. Selipsky spent 15 years in AWS, while Garman has been with AWS for 18 years, most...
Kirby Insider Sold Shares Worth $285,828, According to a Recent SEC Filing
Kirby Insider Sold Shares Worth $285,828, According to a Recent SEC Filing
May 14, 2024
10:01 AM EDT, 05/14/2024 (MT Newswires) -- Dorman Lynn Strahan, President, Kirby Engine Systems, on May 10, 2024, sold 2,470 shares in Kirby (KEX) for $285,828. Following the Form 4 filing with the SEC, Strahan has control over a total of 18,584 shares of the company, with 18,584 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/56047/000095017024059171/xslF345X03/ownership.xml Price: 114.25, Change: -0.16, Percent Change:...
Apellis Pharmaceuticals Enters Into Senior Secured Credit Facility With Sixth Street
Apellis Pharmaceuticals Enters Into Senior Secured Credit Facility With Sixth Street
May 14, 2024
10:02 AM EDT, 05/14/2024 (MT Newswires) -- Apellis Pharmaceuticals ( APLS ) said Tuesday it entered into a senior secured credit facility of up to $475 million with Sixth Street, with roughly $375 million financed at completion. Under the terms, Apellis can draw a further $100 million before September 2025, the biopharmaceutical company added. The new credit facility will mature...
Copyright 2023-2026 - www.financetom.com All Rights Reserved